$CLVS

Clovis Oncology Inc.

  • NASDAQ
  • Health Technology
  • Biotechnology

PRICE

$6.015 ▲2.296%

Last Close

VOLUME

2,959,080

DAY RANGE

5.58 - 5.93

52 WEEK

2.93 - 17.37

Echofin Members Consensus

profile
thegiz18 #ivtrades Join team
recently

$CLVS still running

profile
dros #droscrew Join team
recently

10000 $CLVS 16OCT20 $5 Ps sold 0.57, 10000 $8 Cs bought 0.46, replaces 580k shares sold

profile
Neptune5045 #StockTraders.NET Join team
recently

and thing about $CLVS is that their drug got approved by FDA

profile
Roberto_Porras #StockTraders.NET Join team
recently

$CLVS nice pop

profile
maletone #StockTraders.NET Join team
recently

damn on $CLVS

profile
maletone #StockTraders.NET Join team
recently

I hope they can keep $CLVS up

profile
maletone #StockTraders.NET Join team
recently

would like a pop in $CLVS

profile
Neptune5045 #StockTraders.NET Join team
recently

$CLVS drug approved by FDA

profile
FUZZJP #ivtrades Join team
recently

$CLVS gaping

BJ
Bjpaul13 #ivtrades Join team
recently

$CLVS activity in the 6c and 8c weeklies

profile
thegiz18 #ivtrades Join team
recently

Big percentage move on $CLVS this morning on volume

BR
brAli #StockTraders.NET Join team
recently

they pumping $CLVS

profile
thegiz18 #ivtrades Join team
recently

$DBX, $DDOG, $CLVS down on earnings

profile
thegiz18 #ivtrades Join team
recently

Earnings after close today include $TTD, $UBER, $DBX, $DDOG, $NET, $FSLR, $CLVS, $CZR

For a live feed join teams on Echofin

Key Metrics

Market Cap

518.63 M

Beta

1.32

Avg. Volume

5.64 M

Shares Outstanding

88.20 M

Yield

0%

Public Float

85.66 M

Next Earnings Date

2020-10-28

Next Dividend Date

Company Information

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

CEO: Patrick J. Mahaffy

Website:

HQ: 5500 Flatiron Parkway Boulder, 80301 CO

Related News

  • Business Wire

    Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting

    10 Sep 2020, 12:05

  • Business Wire

    Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020

    09 Sep 2020, 12:05

  • Seeking Alpha

    FDA OKs FoundationOne CDx as a companion Dx for Clovis Oncology's rucaparib (NASDAQ:CLVS)

    27 Aug 2020, 05:53

  • Business Wire

    FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    26 Aug 2020, 23:23

  • Benzinga

    Why Clovis Oncology's Stock Is Trading Higher Today

    17 Aug 2020, 15:13